London (PRWEB) November 06, 2013
MCD Group continuously researches and monitors emerging drug delivery technologies and has compiled this report to profile some of the innovative developments at younger, emerging companies. The report focuses on start-ups and smaller companies that tend to be less well known, but are expected to gain momentum as they advance their technologies and produce significant clinical data. All of the companies profiled have interest in forming new partnerships or receiving funding to enable further development and eventual commercialization of their technologies.
The report features profiles of 62 companies, a majority of which were founded in the past five years. Most are located in the United States; however a few profiled companies are based in Canada, Europe, and Australia. Approximately 50% of the companies are affiliated with a University, and ten companies have initiated human clinical trials.
Collectively, the emerging companies profiled in this report are focused on 11 different therapeutic categories. Oncology is the leading focus among companies investigated, and approximately 25 percent of the companies profiled are developing proprietary technologies designed to improve delivery of macromolecules/biologics. Another 25 percent of the companies are focused on novel delivery devices, ranging from inhalation and nasal devices, to more patient-friendly injectable systems. All of the companies investigated are developing technologies that could potentially transform drug delivery in one or more therapeutic areas.
For each company profiled, the following information is provided:
•Detailed Technology Description
•Development Status / Pipeline Products
•Patents and Publications
•Partnership and Funding Opportunities
•Business Development & Licensing Contact
Examples of Technologies Presented
•Mini-pump for subcutaneous delivery of IV medications
•Targeted nanoparticle micelles
•Abuse-deterrent delivery system
•Dry powder particle processing technology
•Oral capsule technology for biologics
•Nanovesicle delivery system for delivery across the blood-brain barrier
•Timed-release intra-ocular implant device
•Non-invasive aerosol device for brain drug delivery
•Extracellular drug conjugate technology
•Nanoparticles and novel device for CNS and inner ear drug delivery
•Next-generation auto-injector technology
•Nanopolymer drug conjugates
•Microneedle patch system
•Pocket-sized ultrasound delivery device
•Biodegradable, topical drug patch
Sample of Companies Profiled
Reasons to Buy
•Identify early stage delivery technologies that will potentially "enable" the delivery of your therapeutic compound
•Learn about investment opportunities with emerging companies, to gain access to promising, early stage technologies
•Identify novel drug delivery formulations available for partnering, to enhance your product portfolio
Table of Contents
Figure 1: Featured Companies by Year Founded
Figure 2: Featured Early Stage Technologies by Delivery Route
Table 1: Sample of Emerging Parenteral DDS Companies
Table 2: Sample of Emerging Delivery Devices in Development
Table 3: Ten Novel Pipeline Products of DDS Start-ups
Table 4: Emerging Companies by Therapeutic Focus
Affinity Therapeutics, LLC
AlignBioscience Laboratory, LLC
Alitair Pharmaceuticals, Inc.
Axxia Pharmaceuticals, LLC
Clearside Biomedical, Inc.
Corinthian Ophthalmic, Inc.
Cristal Delivery, B.V.
Ekteino Laboratories, Inc.
EnduRx Pharmaceuticals, Inc.
Engineered BioPharmaceuticals, Inc.
Extend Biosciences, Inc.
Inspirion Delivery Technologies, LLC
Inspiro Medical, Ltd.
Intensity Therapeutics, Inc.
Kala Pharmaceuticals, Inc.
Lauren Sciences, LLC
Lypro Biosciences, Inc.
NanoMedical Systems, Inc.
NanoSmart Pharmaceuticals, Inc.
On Demand Therapeutics, Inc.
Orbis Biosciences, Inc.
OtoMagnetics & Weinberg Medical Physics
Oval Medical Technologies
PolyActiva Pty, Ltd.
Prometheon Pharma, LLC
ProSolus Pharma, LP
Respira Therapeutics, Inc.
Solstice Biologics, LLC
Xeris Pharmaceuticals, Inc.
Read the full report:
For more information:
Research Advisor at Reportbuyer.com
Tel: +44 208 816 85 48
Read the full story at http://www.prweb.com/releases/2013/11/prweb11307459.htm.
Copyright©2012 Vocus, Inc.
All rights reserved